BunyaVax BV was founded in 2017 with the primary objective to commercialize proprietary vaccine technologies developed by Wageningen Bioveterinary Research. BunyaVax has obtained world-wide exclusive rights on the underlying patents. Focus of the company is to further optimize its vaccine technology and to generate early-stage leads for safe and efficacious vaccines for a selection of diseases. Both veterinary and human applications are foreseen.
Located in Lelystad, The Netherlands
BunyaVax has its office and laboratory on the premises of Wageningen Bioveterinary Research (WBVR) in Lelystad in the province of Flevoland, The Netherlands. WBVR has state-of-the-art facilities for vaccine development and vaccine challenge studies. WBVR is part of Wageningen University & Research (WUR) - globally leading in agriculture. BunyaVax and WBVR closely collaborate in the development of the vaccines.
Prof. Eric Claassen PhD
Eric is Professor Knowledge Valorisation in the Life Sciences at Dept. Virology Erasmus MC in Rotterdam. Eric is 20% academic and 80% entrepreneur. He has co-founded more than 20 life sciences companies and is Chairman of the PAB of Pfizer Consumer Health, Chairman of the SAB of Christian Hansen A/S (Probiotics) and the SAB of Forbion life science venture capital. He was also the winner of the Dutch 1 million Euro NGI Valorisation Award for ‘Excellent deal making with Industry.
René Aerts PhD
René retired from Merck/MSD Animal Health in 2013 where he had been a member of the Executive Committee since 2008 as Global Head Vaccine Research. He held senior positions in Manufacturing Operations, Regulatory Affairs and R&D at Intervet International. He advises the executive management of Global Animal Health and Life Sciences companies. This includes support on M&A’s and Integration. René holds various non-executive and Advisory Board positions.
Marianne Boes PhD
Marianne is scientific expert in the field of immunology. She holds a PhD from the Massachusetts Institute of Technology (MIT) in Boston. In 2004 started her research group at the Brigham and Women´s Hospital/Harvard Medical School. In 2008 moved her lab to the Pediatrics department of the University Medical Center Utrecht in the Netherlands. She focuses mainly on immunodeficiencies, immune activation and also on translational immunology and cancer immunotherapy.
Danny Goovaerts DVM
Executive with more than 23 years of experience and strong scientific background in Vaccine R&D and Production of vaccines. Worked in senior positions for Intervet International. Experience in due diligence, product transfers, R&D organization. Major expertise in Veterinary Medicine, in particular in the control of transboundary animal diseases, FMD research and production, Vaccine R&D, Regulatory Affairs and licensing in EU, USA, India and global.